OR WAIT null SECS
November 23, 2023
Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms.
November 16, 2023
Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.
November 15, 2023
Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.
October 18, 2023
Spark Therapeutics and SpliceBio have formed a collaboration to develop a gene therapy that can treat an inherited retinal disease.
The California Institute for Regenerative Medicine has partnered with Forge Biologics, which will manufacture AAVs to help accelerate gene therapy programs in California.
October 13, 2023
Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.
October 12, 2023
Salipro Biotech and Icosagen have entered into a multi-target collaboration to discover and characterize monoclonal antibodies.
October 11, 2023
Under this agreement, Acuitas Therapeutics’ LNP technology platform will be transferred to BIOVECTRA for use in manufacturing mRNA-based therapies.
Roche will gain exclusive worldwide rights to develop, manufacture, and commercialize Ionis’ investigational RNA-based therapeutic candidates for Alzheimer's and Huntington's disease.
October 10, 2023
Orakl Oncology has raised funds to develop its precision oncology platform and accelerate drug development.